Introduction
Stroke clinical practice has benefited from advances such as recombinant tissue plasminogen activator (rt-PA) administration within 4·5 h of stroke onset (1), decompressive surgery for patients with malignant middle cerebral artery occlusion (2) , endovascular approaches (3), early supported discharge (4) , and the use of stroke units to facilitate recovery (5) . However, many trials have failed to show efficacy. The value of trial data can be maximized through reuse in novel exploratory analyses.
We previously reported on the development of the Virtual International Stroke Trials Archive (VISTA) (6) . Research arising from VISTA has been published in 34 peer-reviewed reports (Appendix 1) and has identified areas for improvement in current practice (7) (8) (9) . The rapid success of VISTA encouraged the extension of trial data collection to other forms of clinical stroke research, namely prevention, rehabilitation, imaging, intracerebral haemorrhage (ICH), registers, and observational studies. In addition to expanding our datasets, we sought to improve the overall service provided by VISTA.
Methods
Since 2008, we have established VISTA-Rehab, VISTA-Prevention, VISTA-ICH, and VISTA-Plus (covering registries and observational data). Through collaboration with the Stroke Imaging Repository based in Bethesda, MD, and the MR-Stroke Group based in Melbourne, Australia, we developed VISTA-Imaging, a repository of anonymized source magnetic resonance imaging (MRI) and computed tomography (CT) images ( Fig. 1 ).
Eligibility criteria
We formulated eligibility criteria specific to each section of VISTA for entry of datasets (Table 1 ). Since we cannot anticipate every possible need for data, there is some flexibility in these criteria, and VISTA-Plus in particular also serves as a repository for less mainstream datasets.
Steering committee
The role of the steering committee is well established (6) . For the new subsections, an active member has taken on the role of Chairperson (Appendix 2).
Data access, storage, and management
Established data access and management policies apply to all VISTA archives (6, 10) . Briefly, investigators can access data by submitting a research proposal. Following approval by the relevant Steering Committee, data are compiled and sent to the investigator. On completion, off-site copies of the anonymized data are deleted.
Communication
The VISTA web site (http://www.vistacollaboration.org) was further developed to accommodate the expansion of the resource. We established dedicated e-mail addresses (Appendix 2) to notify the relevant coordinators and chairpersons of new projects, expedite the circulation of proposals, data compilation, and access. Data on the trials and registries within each section are available on the VISTA web site. Documented consent or waiver of consent following local IRB-approved procedure Submitted dataset is devoid of patient identifiers Documented selection criteria Minimum imaging datasets-for MRI † † : DWI ‡ ‡ (including b0 and b1000 images) PWI § § (gadolinium bolus tracking). All additional standard sequences that are available at the initial and subsequent time points should be included (e.g. GRE |||| , MRA ## , FLAIR***, and T2WI † † † ). For CT: noncontrast CT ‡ ‡ ‡ , CTA § § § , and perfusion CT. Clinical assessment includes recording of neurological deficit by NIHSS, SSS or similar, at baseline and between 48 h and six-months; stroke subtype by Oxford, TOAST classification |||||| , or similar at baseline and final diagnosis. Confirmation of stroke diagnosis by cerebral imaging.
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VISTA-Plus
Clinical diagnosis of stroke Patients included in a cohort study or stroke registry Baseline assessment includes recording of a recognized stroke severity/impairment measure, e.g. Barthel Index, NIHSS, SSS, or similar. Outcome assessment includes recording of a recognized stroke severity/impairment measure, e.g. Barthel, mRS ### , NIHSS, or similar. Study was conducted within the last 15 years. 
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Collaborative opportunities
Our system of international peer review ensures that investigators have access to a wealth of expertise, statistical consultation, and methodological advice from the early project development phase. VISTA hosts annual Steering Committee and Collaborators' meetings at the International and European Stroke Conferences, providing investigators with an opportunity to discuss policy issues, develop new projects with leading international investigators, and disseminate recent findings. Within this network, we encourage the development of young researchers through training opportunities, under the supervision of leading researchers.
Funding
VISTA is supported financially by capacity-building contributions from active investigators, with a discounted level for academic vs. industry investigations. Funding supports data storage, continued development, and day-to-day administration of the resource.
Results
We have collated data within six stroke archives:
VISTA-Acute
Acute stroke data are available on 28 190 patients, with a median age of 71 [interquartile range (IQR) (61,78)], baseline National Institutes of Health Stroke Scale (NIHSS) score of 11 [IQR (6, 17) ], and 90-day modified Rankin score of 3 [IQR (1, 4) , Table 2a ]. Variables available from most trials include initial stroke severity, age, sex, stroke onset to treatment time, medical history, country of recruitment, modified Rankin scale (mRS), NIHSS, concomitant medications, and adverse events.
Since Weimar's review of VISTA in 2009 describing 16 completed projects (11), 15 further papers have been published (Appendix 1). Analyses have informed thrombolysis in the elderly, in patients with diabetes and prior stroke (8), and have described the beneficial effects of thrombolysis in patients across a wide range of stroke severity (7) . These results have implications for future investigations of acute stroke management.
VISTA-Rehab
The initial development of VISTA-Rehab has been detailed previously (10) . As of March 2011, we held data on 10 194 patients ( 
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Due to the wide range of trial outcome measures employed in rehabilitation trials, the collation of such data presents unique challenges for VISTA-Rehab. Accordingly, we have identified key areas for trial recruitment such as communication and cognitive impairment, upper limb rehabilitation and continence. This has facilitated the collation of data in specialist areas while increasing data availability of common outcome measures related to each area. Recruitment to VISTA-Rehab is ongoing and planned investigations include vision, communication, and continence issues after stroke. Ongoing work on poststroke impairments and quality of life utilize data from VISTA-Rehab in conjunction with eligible data from the other VISTA domains.
VISTA-Prevention
Trial recruitment to VISTA-Prevention is ongoing. We currently have no data available for analysis. However, a single patient meta-analysis of the major trials investigating antiplatelet therapy in secondary stroke prevention is currently underway. After publication of this analysis, data from European Stroke Prevention Study 2 (ESPS2) (12), European/ Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) (13), Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) (14) , Management of ATherothrombosis with Clopidogrel in High-risk patients (MATCH) (15) , Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) (16) , and Prevention Regimen For Effectively avoiding Second Strokes (PRoFESS) (17) will be transferred to VISTA-Prevention and will be accessible for analyses.
VISTA-ICH
A separate archive of patients with ICH was developed from the acute stroke material. We currently hold data on 1829 patients with ICH. Data available from most trials include initial stroke severity (baseline NIHSS median 14, IQR [9, 18] ), age [median 67, IQR (58,75)], sex, onset to treatment time, medical history, lesion volume, presence of intraventricular haemorrhage (IVH), and outcomes by mRS [median 2 at 90 days, IQR (1,4)] and NIHSS [median 4 at 90 days, IQR (2, 9) , Table 2c ]. Original CT films, scanned images or Digital Imaging and Communications in Medicine (DICOM) files are available for at least 1250 patients.
Exploratory analyses using these data include studies of hyperthermia and functional outcome in patients with ICH, and validation studies on the Graeb scoring system for IVH.
VISTA-Imaging
DICOM Imaging data are available for 375 patients. VISTA-Imaging contains variables on age, sex, race, ethnicity, initial and final diagnoses, onset times, NIHSS, mRS, Barthel, and clinical trial enrolment information (Table 2d) . At present, we do not store image analyses, only MRI scans including diffusion-weighted imaging, perfusion imaging, gradient-echo, and magnetic resonance angiography at pretreatment and follow-up. We also store the corresponding demographic and clinical data from baseline and follow-up visits (two-hours to 90 days).
The VISTA-Imaging web site (https://stirmrstroke.ninds. nih.gov) controls secure access to the scan database containing all available imaging and clinical data. The repository can be searched according to demographic, clinical, and/or imaging criteria via the web site; however, data may not be downloaded. Instead, requests for access to and receipt of repository data can be submitted on the web site. The repository database and images reside on a dedicated, secure server managed by the stroke laboratory within the National Institute of Neurological Disorders and Stroke at the National Institutes of Health in Bethesda, MD.
VISTA-Plus
VISTA-Plus was established in 2009 to handle registries, observational, and population data (Table 2e ). Currently data are available on 6573 patients with contribution of one further registry planned shortly.
Discussion
We developed and expanded a valuable stroke resource through collaboration with investigators in clinical practice, academia, and industry. This resource has been successfully used over the past 10 years to examine acute stroke research questions, and we anticipate that future work in the expanded sections will benefit the wider stroke research community.
Sharing data in this manner has evident benefits: the cost for research and development of a medical intervention is estimated to be $802 M (USD) (18) , hence there are many reasons to seek to minimize costs and to speed up the research process. Issues such as cognitive decline and communication impairment can form a barrier to consent, thereby influencing the inclusion of participants and trial recruitment rates (19) , increasing research timescales and delaying the translation of findings into clinical practice. Therefore, reducing sample size and optimizing trial end-points while retaining statistical power is an important research focus. Current VISTA work by Fulton et al. seeks to guide sample size limitation and strengthen end-points (unpublished). Recent work by Mishra et al. found that 'home time' was a responsive outcome measure and could be included as a complementary outcome in stroke trials (20) . VISTA can also be used to generate and test new hypotheses: current work involves the validation of the Graeb Scale and Safe Implementation of Treatments in Stroke-Intracerebral Haemorrhage (SITS-ICH) Risk Score.
VISTA policy does not permit the reexamination of treatment effects within specific trials, and as data are derived from clinical trials, inferences are made to the trial-eligible patient population rather than the general stroke population. In this way, VISTA differs from Cochrane Systematic Reviews, which carry out meta-analyses to explore therapeutic efficacy. While we do not advocate the use of secondary analysis to replace conventional randomized, controlled trials (RCTs), VISTA can be used to supplement RCT findings, inform the development, design and conduct of future RCTs, or examine patient subgroups. Analyses of secondary data could be integrated into clinical decisions and considered in the development of clinical guidelines with recognition of the lower level of evidence they offer.
VISTA has evolved into a resource that facilitates much more than secondary data analysis. With dataset expansions in place, VISTA offers a complete package for stroke researchers, granting access to networks of researchers, statistical consultation, and a wealth of data for use in epidemiology, proof-of-concept, end-point optimization, and pilot studies. The current approach taken by VISTA is a model not only for other stroke fields as we have described but also for other disease areas.
